Compass Therapeutics, Inc. develops clinical-stage, oncology-focused antibody therapeutics targeting angiogenesis, immune activation and tumor-driven immunosuppression. News about CMPX centers on its antibody pipeline, including tovecimig, a DLL4 x VEGF-A bispecific antibody studied with paclitaxel in biliary tract cancer, and earlier-stage programs such as CTX-8371, CTX-10726 and CTX-471.
Recurring updates cover clinical trial results, FDA-related regulatory designations and interactions, medical-meeting presentations, pipeline expansion, financial results, cash resources, leadership changes and equity inducement grants under Nasdaq rules.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.